← Back to Search

Exercise for Breast Cancer Patients Undergoing Chemotherapy

N/A
Recruiting
Research Sponsored by University of Virginia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of breast cancer (Stage I-III or IV with minimal burden) and prescribed chemotherapy (TC, AC, TCHP, TCH with or without Pembrolizumab)
Age 18 years or over
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 22 weeks
Awards & highlights

Study Summary

This trial tests if exercise can help reduce side effects of chemo, like heart problems and fatigue, and improve quality of life.

Who is the study for?
This trial is for adults over 18 with breast cancer (Stage I-III or minimal burden IV) who are about to start certain chemotherapies and can exercise. They must be cleared by a doctor, speak English, and not have had cardiotoxic chemo before. People with recent severe heart issues, uncontrolled high blood pressure, major organ diseases, pregnancy, or conditions that make exercising unsafe cannot join.Check my eligibility
What is being tested?
The study tests if two types of exercise—moderate intensity walking and high-intensity interval training—can reduce the negative effects of chemotherapy on heart health, inflammation levels, and life quality in breast cancer patients.See study design
What are the potential side effects?
While specific side effects aren't listed for the exercises being tested in this trial, typical risks might include muscle soreness or strain from physical activity. The safety of participants will be monitored throughout.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have breast cancer (early or minimal stage IV) and am on specific chemotherapy.
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~22 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 22 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Subject Retention Percentage
Secondary outcome measures
Blood pressure
Brachial Artery Endothelium-Dependent Flow-Mediated Dilation
Carotid-Femoral Pulse Wave Velocity
+6 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Moderate Intensity WalkingExperimental Treatment1 Intervention
Subjects allocated to moderate intensity walking will be given a gift card to purchase a paid of running shoes. A chest-based heart rate monitor and an activity tracker watch will be provided. Subjects will aim to achieve 150 minutes a week of moderate intensity walking. Subjects will also be receiving text messages, phone calls, and emails from study staff to gauge and encourage subject participation and physical activity.
Group II: High Intensity Interval ExerciseExperimental Treatment1 Intervention
Subjects will receive a recumbent bike to be delivered and assembled to their home as well as a heart rate monitor and activity tracker. Subjects will undergo high intensity interval exercise 3 days a week, with the goal of achieving 85-90% of their heart rate max. Subjects will also be receiving text messages, phone calls, and emails from study staff to gauge and encourage subject participation and physical activity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
High Intensity Interval Exercise
2021
N/A
~90

Find a Location

Who is running the clinical trial?

University of VirginiaLead Sponsor
753 Previous Clinical Trials
1,245,015 Total Patients Enrolled

Media Library

High Intensity Interval Exercise Clinical Trial Eligibility Overview. Trial Name: NCT05786014 — N/A
Cardiovascular Disease Research Study Groups: High Intensity Interval Exercise, Moderate Intensity Walking
Cardiovascular Disease Clinical Trial 2023: High Intensity Interval Exercise Highlights & Side Effects. Trial Name: NCT05786014 — N/A
High Intensity Interval Exercise 2023 Treatment Timeline for Medical Study. Trial Name: NCT05786014 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any slots available for participation in this research study?

"As indicated by the clinicaltrials.gov database, this medical trial is no longer actively enrolling patients as its last edit was on March 23rd 2023. Nonetheless, there are 3072 other studies searching for volunteers at present."

Answered by AI
~11 spots leftby Jan 2025